BACKGROUND: Clinical benefit from cytotoxic chemotherapy for metastatic papillary thyroid carcinoma (PTC) is disappointing, and effective therapeutic approaches for these patients are urgently needed. Because kinase-activating mutations in the BRAF proto-oncogene commonly occur in advanced PTC, and inhibition of BRAF(V600E) has shown promising clinical activity in melanoma, BRAF inhibitor therapy may be an effective strategy to treat metastatic PTC. METHODS: The dose escalation portion of a first-in-human, phase I study of vemurafenib, a selective RAF inhibitor, included three patients with metastatic PTC harboring the BRAF(V600E) mutation. Vemurafenib was initially dosed at 240-360 mg twice a day, later escalated to 720 mg twice a day. Response evaluation was performed every 8 weeks per Response Evaluation Criteria in Solid Tumors (RECIST). RESULTS: Among the three patients, one had a confirmed partial response with reduction of pulmonary target lesions by 31%, and the duration of response was 7.6 months before the disease progressed in the lungs and the bones. The time to progression was 11.7 months. The other two patients had stable disease, and the time to progression was 13.2 and 11.4 months, respectively. CONCLUSIONS: Vemurafenib appears to have a promising clinical activity in patients with metastatic PTC, and our data suggest that the BRAF(V600E) mutant kinase is a relevant target for therapy in this patient population. Further investigation of inhibitors of mutated BRAF kinase in patients with PTC in a phase II study is warranted.
BACKGROUND: Clinical benefit from cytotoxic chemotherapy for metastatic papillary thyroid carcinoma (PTC) is disappointing, and effective therapeutic approaches for these patients are urgently needed. Because kinase-activating mutations in the BRAF proto-oncogene commonly occur in advanced PTC, and inhibition of BRAF(V600E) has shown promising clinical activity in melanoma, BRAF inhibitor therapy may be an effective strategy to treat metastatic PTC. METHODS: The dose escalation portion of a first-in-human, phase I study of vemurafenib, a selective RAF inhibitor, included three patients with metastatic PTC harboring the BRAF(V600E) mutation. Vemurafenib was initially dosed at 240-360 mg twice a day, later escalated to 720 mg twice a day. Response evaluation was performed every 8 weeks per Response Evaluation Criteria in Solid Tumors (RECIST). RESULTS: Among the three patients, one had a confirmed partial response with reduction of pulmonary target lesions by 31%, and the duration of response was 7.6 months before the disease progressed in the lungs and the bones. The time to progression was 11.7 months. The other two patients had stable disease, and the time to progression was 13.2 and 11.4 months, respectively. CONCLUSIONS:Vemurafenib appears to have a promising clinical activity in patients with metastatic PTC, and our data suggest that the BRAF(V600E) mutant kinase is a relevant target for therapy in this patient population. Further investigation of inhibitors of mutated BRAF kinase in patients with PTC in a phase II study is warranted.
Authors: R Michael Tuttle; Douglas W Ball; David Byrd; Raza A Dilawari; Gerard M Doherty; Quan-Yang Duh; Hormoz Ehya; William B Farrar; Robert I Haddad; Fouad Kandeel; Richard T Kloos; Peter Kopp; Dominick M Lamonica; Thom R Loree; William M Lydiatt; Judith C McCaffrey; John A Olson; Lee Parks; John A Ridge; Jatin P Shah; Steven I Sherman; Cord Sturgeon; Steven G Waguespack; Thomas N Wang; Lori J Wirth Journal: J Natl Compr Canc Netw Date: 2010-11 Impact factor: 11.908
Authors: Keith T Flaherty; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Peter J O'Dwyer; Richard J Lee; Joseph F Grippo; Keith Nolop; Paul B Chapman Journal: N Engl J Med Date: 2010-08-26 Impact factor: 91.245
Authors: Maria E Cabanillas; Steven G Waguespack; Yulia Bronstein; Michelle D Williams; Lei Feng; Mike Hernandez; Adriana Lopez; Steven I Sherman; Naifa L Busaidy Journal: J Clin Endocrinol Metab Date: 2010-04-14 Impact factor: 5.958
Authors: Keith C Bible; Vera J Suman; Julian R Molina; Robert C Smallridge; William J Maples; Michael E Menefee; Joseph Rubin; Kostandinos Sideras; John C Morris; Bryan McIver; Jill K Burton; Kevin P Webster; Carolyn Bieber; Anne M Traynor; Patrick J Flynn; Boon Cher Goh; Hui Tang; Susan Percy Ivy; Charles Erlichman Journal: Lancet Oncol Date: 2010-09-17 Impact factor: 41.316
Authors: Georgia Hatzivassiliou; Kyung Song; Ivana Yen; Barbara J Brandhuber; Daniel J Anderson; Ryan Alvarado; Mary J C Ludlam; David Stokoe; Susan L Gloor; Guy Vigers; Tony Morales; Ignacio Aliagas; Bonnie Liu; Steve Sideris; Klaus P Hoeflich; Bijay S Jaiswal; Somasekar Seshagiri; Hartmut Koeppen; Marcia Belvin; Lori S Friedman; Shiva Malek Journal: Nature Date: 2010-02-03 Impact factor: 49.962
Authors: Gideon Bollag; Peter Hirth; James Tsai; Jiazhong Zhang; Prabha N Ibrahim; Hanna Cho; Wayne Spevak; Chao Zhang; Ying Zhang; Gaston Habets; Elizabeth A Burton; Bernice Wong; Garson Tsang; Brian L West; Ben Powell; Rafe Shellooe; Adhirai Marimuthu; Hoa Nguyen; Kam Y J Zhang; Dean R Artis; Joseph Schlessinger; Fei Su; Brian Higgins; Raman Iyer; Kurt D'Andrea; Astrid Koehler; Michael Stumm; Paul S Lin; Richard J Lee; Joseph Grippo; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Paul B Chapman; Keith T Flaherty; Xiaowei Xu; Katherine L Nathanson; Keith Nolop Journal: Nature Date: 2010-09-30 Impact factor: 49.962
Authors: Roch-Philippe Charles; Jillian Silva; Gioia Iezza; Wayne A Phillips; Martin McMahon Journal: Mol Cancer Res Date: 2014-04-25 Impact factor: 5.852
Authors: Svetlana A Protsenko; Anna I Semionova; Yuri I Komarov; Svetlana N Aleksakhina; Alexandr O Ivantsov; Aglaya G Iyevleva; Evgeny N Imyanitov Journal: Invest New Drugs Date: 2015-08-20 Impact factor: 3.850
Authors: Marcia S Brose; Maria E Cabanillas; Ezra E W Cohen; Lori J Wirth; Todd Riehl; Huibin Yue; Steven I Sherman; Eric J Sherman Journal: Lancet Oncol Date: 2016-07-23 Impact factor: 41.316